ADVOCATE. CONNECT. INNOVATE.

Category Archives: Washington

New Legislator Spotlight: Congressman Mike Levin (D-San Juan Capistrano)

On behalf of our membership and California’s statewide life sciences community – a sector which employs over 311,000 Californians – California Life Sciences Association (CLSA) welcomes Congressman Mike Levin (D-San Juan Capistrano). We look forward to working with Congressman Levin and his team to advance policies that improve patient health and bring positive change for California patients and their families.

CLSA Submits Recommendations to House W&M and E&C Leadership on Lowering Medicare Part D Costs for Seniors

Late last month, House Ways and Means Committee Chairman Richard Neal (D-Mass.) and Ranking Member Kevin Brady (R-Texas), and House Energy and Commerce Committee Chairman Frank Pallone (D-N.J.) and Ranking Member Greg Walden (R-Ore.), released a discussion draft text of legislation proposing updates to reform and improve the Medicare Part D program. In coordination with our membership, CLSA submitted comments to Committee Leadership in support of the concept of a cap or limit on the amount that seniors pay out-of-pocket for prescription drugs in Part D.

CLSA Endorses SEC-proposed Changes to Sarbanes-Oxley to Provide Regulatory Relief to Small & Emerging Companies

In May 2019, the Securities and Exchange Commission (SEC) proposed a new rule to expand the universe of small public companies exempt from Sarbanes-Oxley (SOX) Section 404(b) to companies with annual revenues of less than $100 million. SOX 404(b) was established with the intent to protect investors against corporate fraud by increasing the quality of a company’s financial reporting via enhanced transparency and auditor oversight of internal control systems.

CLSA & Allied Stakeholders Succeed in Halting Administration’s Final Rule on Six Protected Classes in Medicare Part D

On Thursday, May 16, CLSA’s advocacy paid off when CMS released its final rule and fact sheet. In the final rule, CMS decided to not adopt two proposals which would have allowed Part D plans to exclude a protected class drug from their formularies for multiple years if price-growth exceeded an inflation index as well as if the drug represented a new formulation that is not a significant innovation over the original product.

New Legislator Spotlight: Congresswoman Katie Hill (D-Simi Valley)

On behalf of our membership and California’s statewide life sciences community – a sector which employs over 311,000 Californians – California Life Sciences Association (CLSA) welcomes Congresswoman Katie Hill (D-Simi Valley). We look forward to working with Congresswoman Hill and her team to advance policies that improve patient health and bring positive change for California patients and their families.

Legislation to Repeal Device Tax Introduced in House with Strong Bipartisan Support

On April 10, 2019, Reps. Ron Kind (D-Wisc.) and Jackie Walorski (R-Ind.) – together with Reps. Scott Peters (D-San Diego), Terri Sewell (D-Ala.), Suzan DelBene (D-Wash.), Darin LaHood (R-Ill.), Jason Smith (R-Mo.) and Rich Hudson (R-N.C.) – introduced legislation to permanently repeal the medical device excise tax, known as the Protect Medical Innovation Act of 2019 (H.R. 2207).  CLSA is strongly supportive of this legislation and actively encouraged members of the California congressional delegation to lend their support as cosponsors.